$8.19
-0.97%BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
BBOT • NASDAQ
| BridgeBio Oncology Therapeutics Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
373.7M | 1.7M | 0.0 | 0.0 | 0.0 | |
51.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
425.5M | 1.7M | 0.0 | 0.0 | 0.0 | |
386K | 0.0 | 0.0 | 0.0 | 0.0 | |
386K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 252K | 0.0 | 0.0 | 0.0 | |
-386K | 0.0 | 0.0 | 0.0 | 0.0 | |
425.5M | 1.9M | 0.0 | 0.0 | 0.0 | |
NON-CURRENT ASSETS | |||||
132K | 192.4M | 0.0 | 0.0 | 0.0 | |
22.8M | 25.1K | 332.9K | 144.6K | 144.3K | |
22.9M | 192.5M | 332.9K | 144.6K | 144.3K | |
448.4M | 194.4M | 332.9K | 144.6K | 144.3K | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
1.4M | 67.8K | 0.0 | 0.0 | 0.0 | |
1.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 67.8K | 0.0 | 0.0 | 0.0 | |
0.0 | 119.7K | 326.4K | 123.3K | 125.7K | |
522K | 0.0 | 70.1K | 43.1K | 37K | |
33.1M | 0.0 | 0.0 | 0.0 | 0.0 | |
35M | 187.5K | 396.5K | 166.5K | 162.6K | |
NON-CURRENT LIABILITIES | |||||
2.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 5.5M | 0.0 | 0.0 | 0.0 | |
2.2M | 5.5M | 0.0 | 0.0 | 0.0 | |
37.3M | 5.7M | 396.5K | 166.5K | 162.6K | |
SHAREHOLDERS' EQUITY | |||||
8K | 192.4M | 460.0 | 288.0 | 288.0 | |
767.6M | 0.0 | 24.5K | 24.5K | 24.7K | |
-356.6M | -3.7M | -88.6K | -46.9K | -43.4K | |
16K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 172.0 | 0.0 | |
411.1M | 188.7M | -63.6K | -21.9K | -18.4K | |
411.1M | 188.7M | -63.6K | -21.9K | -18.4K | |
SUMMARY | |||||
448.4M | 194.4M | 332.9K | 144.6K | 144.3K | |
51.9M | 192.4M | 0.0 | 0.0 | 0.0 | |
2.8M | 0.0 | 70.1K | 43.1K | 37K | |
-370.9M | -1.7M | 70.1K | 43.1K | 37K | |
79,196,710 | 79,196,710 | 79,196,710 | 79,196,710 | 79,196,710 |
BBOT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Continue your BBOT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.